Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient
文献类型：期刊论文
| 作者 | Li, Wen1,2; Liu, Ruixin1,2; Li, Xuelin1,2; Tao, Bei1,2; Zhai, Nan1,2; Zhang, Yifei1,2; Gu, Weiqiong1,2; Wang, Weiqing1,2; Ning, Guang1,2; Wang, Xiaolin5 |
| 刊名 | JOURNAL OF DIABETES
 |
| 出版日期 | 2019 |
| 卷号 | 11期号:12页码:982-992 |
| 关键词 | bile acids dipeptidyl peptidase-4 inhibitor obesity saxagliptin type 2 diabetes |
| ISSN号 | 1753-0393 |
| DOI | 10.1111/1753-0407.12956 |
| 文献子类 | Article |
| 英文摘要 | Background The aim of the present study was to investigate the metabolic benefits of saxagliptin and its effects on serum bile acids (BAs) in normal weight and overweight/obese drug-naive type 2 diabetes (T2D) patients. Methods In all, 282 drug-naive T2D patients (123 normal weight [NW], with body mass index [BMI] between 19.0 and <25.0 kg/m(2); 159 overweight/obese [OW/OB], with BMI >= 25.0 kg/m(2)) were enrolled in the study and treated with saxagliptin 5 mg daily for 24 weeks. Serum BAs were assayed by liquid chromatography with tandem mass spectrometry. Results At 24 weeks, HbA1c was significantly reduced in both groups, but the HbA1c levels were lower in the OW/OB than NW group. Moreover, significant decreases were seen at 24 weeks in C-reactive protein (CRP), aspartate aminotransferase, alanine aminotransferase, waist circumference, and systolic blood pressure in the OW/OB group. Interestingly, cholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid (GDCA), and glycoursodeoxycholic acid (GUDCA) were increased in both groups after treatment, whereas chenodeoxycholic acid and deoxycholic acid (DCA) were specifically increased in the OW/OB group. Increased DCA and GDCA concentrations were significantly associated with decreased HbA1c or fasting blood glucose and CRP levels, whereas increased GDCA and GUDCA concentrations were associated with decreased waist circumference in the OW/OB group during treatment. In the NW group, increased GUDCA concentrations were significantly associated with a decrease in HbA1c. Conclusions Type 2 diabetes patients with OW/OB exhibited greater improvement in glycemic control and additional metabolic benefits after saxagliptin treatment. Saxagliptin significantly increased the BA pool, and DCA and GDCA were associated with metabolic improvements in OW/OB T2D patients. |
| 学科主题 | Endocrinology & Metabolism |
| WOS关键词 | DIPEPTIDYL PEPTIDASE-4 INHIBITORS ; Y GASTRIC BYPASS ; INSULIN-RESISTANCE ; GUT MICROBIOME ; FATTY LIVER ; WEIGHT-LOSS ; RECEPTOR ; METFORMIN ; IDENTIFICATION ; INFLAMMATION |
| 语种 | 英语 |
| WOS记录号 | WOS:000481367900001 |
| 出版者 | WILEY |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.144/handle/331004/538]  |
| 专题 | 中国科学院上海生命科学研究院营养科学研究所 |
| 作者单位 | 1.Shanghai Inst Endocrinol, Shanghai, Peoples R China; 2.Shanghai Jiao Tong Univ, Dept Endocrine & Metab Dis,Ruijin Hosp, Shanghai Key Lab Endocrine Tumours,Shanghai Clin, Shanghai Inst Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China; 3.Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China, 4.Chinese Acad Sci, Lab Endocrinol & Metab, Inst Hlth Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China; 5.Chinese Acad Sci, Key Lab Separat Sci Analyt Chem, Dalian Inst Chem Phys, Dalian, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Li, Wen,Liu, Ruixin,Li, Xuelin,et al. Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient[J]. JOURNAL OF DIABETES,2019,11(12):982-992. |
| APA | Li, Wen.,Liu, Ruixin.,Li, Xuelin.,Tao, Bei.,Zhai, Nan.,...&,.(2019).Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient.JOURNAL OF DIABETES,11(12),982-992. |
| MLA | Li, Wen,et al."Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient".JOURNAL OF DIABETES 11.12(2019):982-992. |
入库方式： OAI收割
来源：上海营养与健康研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。